Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc: Vestal Point Capital, LP and Ryan Wilder report shared beneficial ownership of 2,766,868 ADS, representing 5.5% of the class. The percentage is calculated using 50,695,078 shares outstanding as of January 31, 2026 from the company's Form 10-K. The filing states the ADSs are directly held by the Vestal Point Fund and Account and lists the reporting persons' business address. The statement is signed by Ryan Wilder on behalf of Vestal Point Capital, LLC and individually on May 15, 2026.
T. Rowe Price Investment Management, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 1,891,600 ADRs of Immunocore Holdings plc, representing 3.7% of the class. The filing lists sole voting and dispositive power over the reported shares and includes a signed declaration dated 05/15/2026.
The filing affirms ownership is 5% or less and contains a customary denial that the filer is the beneficial owner. No transaction details or purchase/sale directions are reported in this excerpt.
Immunocore Holdings plc reported first-quarter 2026 results, led by KIMMTRAK net product revenue of $106.7 million, up from $93.9 million a year earlier, driven by higher volumes in the United States and Europe and broader global reach.
The company generated net income of $13.0 million, compared with $5.0 million in Q1 2025, with diluted earnings per share rising to $0.25 from $0.10. Cash, cash equivalents and marketable securities totaled $844.9 million as of March 31, 2026, supporting an extensive pipeline that includes multiple Phase 3 oncology trials, a Phase 1/2 HIV program, and early-stage autoimmune candidates built on its ImmTAX TCR bispecific platform.
Immunocore Holdings plc reported stronger results for the three months ended March 31, 2026, driven by continued uptake of KIMMTRAK. Revenue from sale of therapies, net rose to $106.7 million, up 13.6% from $93.9 million a year earlier.
The company generated net income of $13.0 million, compared with $5.0 million in the prior-year period, with diluted earnings of $0.25 per share. R&D expenses increased to $61.1 million as Immunocore advanced PRAME-targeted brenetafusp and other pipeline programs, while SG&A declined slightly to $37.9 million.
Immunocore ended the quarter with $452.7 million in cash and cash equivalents and $392.2 million in marketable securities, alongside $402.5 million in principal amount of convertible senior notes maturing in 2030. Management highlighted five-year overall survival data for KIMMTRAK in metastatic uveal melanoma and ongoing late-stage trials, including the PRISM-MEL-301 Phase 3 study.
Immunocore Holdings plc has called its 2026 Annual General Meeting for May 27, 2026, at 2:00 p.m. London time, as a hybrid meeting in London and online via meetnow.global/IHCAGM2026. Ordinary shareholders can attend in person with a QR code or participate electronically.
Shareholders will vote on 10 ordinary resolutions, including the re-appointment of three Class II directors (Siddharth Kaul, William Pao and Kristine Peterson), an advisory say‑on‑pay vote for named executive officers, and approval of the U.K. directors’ remuneration report. Other items cover ratifying and re‑appointing Deloitte LLP as both U.S. independent auditor and U.K. statutory auditor, authorizing the audit committee to set the U.K. audit fee, and receiving and adopting the 2025 U.K. Annual Report.
The final proposal seeks authority for the company and its subsidiaries to make limited political donations and incur political expenditure, capped at £50,000 in each of three categories. The board unanimously recommends that shareholders vote FOR all resolutions. As of April 2, 2026, there were 50,831,928 ordinary shares outstanding and entitled to vote.
Immunocore Holdings Plc submitted a Rule 144 notice to sell 25,000 ADRs. The filing lists a planned sale method as a "Same Day Cashless Exercise and Sale" with a trade date of 04/08/2026 and settlement or delivery date of 04/09/2026. The excerpt also reports two prior ADR dispositions by David Berman totaling 17,797 ADRs on 02/18/2026 and 03/11/2026 with proceeds shown.
Immunocore Holdings Plc reported an insider sale. A holder executed a same-day cashless exercise and sale of 11,832 ADRs on 03/11/2026, with cash proceeds. The filing also records an earlier sale of 5,965 ADRs on 02/18/2026.
T. Rowe Price Investment Management, Inc. amended a Schedule 13G to report beneficial ownership of 3,041,904 ADRs of IMMUNOCORE HOLDINGS PLC as of 02/28/2026, representing 6.0% of the class. The filing lists sole voting and dispositive power over 3,041,904 ADRs.
The filing includes a signature dated 03/06/2026 and a statement denying beneficial ownership. No transaction price, purchase/sale direction, or cash‑flow details are provided in the excerpt.
Immunocore Holdings reported strong 2025 growth from its lead therapy KIMMTRAK while remaining modestly loss-making. KIMMTRAK net sales reached $400.0 million for 2025, up from $310.0 million in 2024, with Q4 2025 sales of $104.5 million versus $84.1 million a year earlier.
Full-year net loss narrowed to $35.5 million from $51.1 million, or $0.71 per share versus $1.02. The company increased investment in its pipeline, with 2025 R&D expenses of $274.9 million and SG&A of $165.4 million. Cash, cash equivalents and marketable securities were $864.2 million as of December 31, 2025.
Management highlighted 15 consecutive quarters of KIMMTRAK revenue growth and ongoing global launches in uveal melanoma, while advancing multiple Phase 3 trials in melanoma, PRAME-targeted programs in solid tumors, an HIV functional cure program, and first autoimmune candidates, with key data readouts anticipated in the second half of 2026.